Bronex

Quick links to important sections

Bronex

Method of action: Antitussive, Expectorant

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bronex

What is Bronex?

Bronex is a pharmaceutical formulation primarily used as an expectorant and mucolytic agent. It is designed to assist in the management of respiratory conditions characterized by the presence of thick, viscous mucus. By altering the physical properties of secretions within the airways, the medication helps facilitate their removal, thereby supporting clearer breathing.

Composition and Classification

The active therapeutic components in Bronex typically belong to classes of medications known as mucolytics or secretolytics. These substances work by breaking down the chemical bonds that hold mucus together, reducing its stickiness and elasticity. This process makes the phlegm thinner and easier to expel through the natural coughing reflex.

Primary Mechanism of Action

Bronex functions by targeting the structure of bronchial secretions. When the respiratory system produces excessive or overly dense mucus—often a response to inflammation or infection—it can become difficult for the cilia (the tiny hairs lining the airways) to move it upward. Bronex acts directly on the mucus components to:

  • Decrease the viscosity of the fluid.
  • Increase the volume of secretions to lubricate the respiratory tract.
  • Enhance the efficiency of the cough mechanism in clearing the lungs.

Common Clinical Uses

This medication is frequently utilized in the context of both acute and chronic respiratory disorders. It is commonly associated with conditions such as:

  • Acute Bronchitis: Helping to clear temporary congestion during a chest cold.
  • Chronic Obstructive Pulmonary Disease (COPD): Assisting in the long-term management of persistent mucus production.
  • Sinusitis: Aiding in the drainage of fluid from the paranasal sinuses.
  • General Chest Congestion: Relieving the sensation of heaviness in the chest caused by accumulated phlegm.

Regulatory References

  1. Guaifenesin: MedlinePlus Drug Information

What side effects are possible with Bronex?

Possible Side Effects and Safety Information

The safety profile of Bronex (Guaifenesin/Pseudoephedrine) is officially documented by regulatory authorities, with adverse reactions generally classified by the affected system-organ class and frequency.

Adverse reactions classified as Common often include effects in the Nervous System and Psychiatric Disorders domains, such as nervousness, insomnia, restlessness, and headache. Gastrointestinal effects like nausea and vomiting are also listed. Effects on the Cardiac and Vascular systems, such as tachycardia (increased heart rate) and hypertension (high blood pressure), are also documented.

Serious adverse reactions, which are officially documented but typically classified as Rare, include specific cardiovascular events (such as myocardial ischaemia), severe skin reactions like Acute Generalized Exanthematous Pustulosis (AGEP), and ischaemic colitis. The official labeling also notes the rare occurrence of hallucinations and convulsions.

Specific Safety Considerations are explicitly stated in regulatory documents for certain patient groups. Older adults may exhibit increased sensitivity to the effects of the sympathomimetic component. The medication is contraindicated (should not be used) in individuals with severe hypertension or severe coronary artery disease. Furthermore, its use is restricted in patients concurrently taking, or having recently stopped taking, Monoamine Oxidase Inhibitors (MAOIs). Safety notes also advise caution for patients with conditions such as prostatic enlargement or diabetes.

Time-related patterns, such as the potential for severe skin reactions to appear within the first two days of treatment and the risk of tolerance and dependency with prolonged use, are also noted in the official regulatory documentation.

Overdose and Emergency Response

Overdose manifestations for the Guaifenesin/Pseudoephedrine combination are primarily driven by the toxicity of the sympathomimetic amine component, Pseudoephedrine. Regulatory documents list acute signs of central nervous system (CNS) overstimulation, including severe restlessness, excitement, hallucinations, and tremor. Cardiovascular effects are also documented, encompassing hypertension (increased blood pressure), tachycardia (rapid heart rate), and various cardiac arrhythmias.

Severe Outcomes

Life-threatening outcomes reported in regulatory profiles include convulsions (seizures) and, in severe cases, cardiovascular collapse or intracranial haemorrhage related to hypertensive crisis. The official profile notes that overdose of the expectorant component in very large doses has been associated with the potential for renal calculi. Increased risk for severe consequences is noted for patients with conditions such as uncontrolled hypertension or severe renal impairment.

Required Emergency Action

Official regulatory labeling mandates that individuals seek immediate medical help or contact a Poison Control Center right away in all cases of suspected overdose. Immediate medical attention is required for the management of acute symptoms. Treatment is defined as symptomatic and supportive, aiming to stabilize the patient, control seizures, and manage blood pressure. No specific antidote is known for this combination product.

Therapeutic Uses of Bronex

What Bronex Treats: Main Uses and Benefits

Bronex (Guaifenesin/Pseudoephedrine) is commonly used to help manage symptoms associated with acute respiratory illnesses and seasonal allergic responses. It is primarily applied across domains where additional symptomatic support is needed for symptoms related to physical discomfort arising from congestion.

The medication is relevant in clinical settings that involve acute or unstable symptom patterns, such as the common cold, flu, and upper respiratory allergies like hay fever. The combination is used in situations involving distressing symptoms that cluster into patterns requiring supportive management. It is helpful in situations where multiple symptoms occur together, such as nasal obstruction and a productive cough.

It provides support that helps ease the overall symptom burden and contributes to easing discomfort by addressing congestion in both the upper and lower airways. “It is applied when symptoms create noticeable functional strain, offering temporary relief from dual respiratory discomfort.”


Quick Fact: Relief for Dual Discomfort

Bronex is commonly used to help with acute symptomatic episodes characterized by nasal blockage and chest congestion, offering symptomatic assistance when both issues coexist.

Regulatory References

  1. NIH DailyMed drug labeling information

Eligibility and Restrictions for Use

Who Can and Cannot Use Bronex?

The population eligibility rules for Bronex (Guaifenesin/Pseudoephedrine) are defined by regulatory labeling, establishing clear boundaries for its use. This medicine is intended for use by adults and children 12 years and older, provided no formal contraindications are present.


Absolute Exclusions (Do Not Use)

Condition / Population Status Basis
Current or recent MAO Inhibitor (MAOI) use (within 2 weeks) Contraindicated Risk of Severe Interaction
Known allergy (hypersensitivity) to ingredients Contraindicated Allergic Reaction Risk
Children under 12 years of age (for extended-release tablets) Prohibited Safety Not Established

Conditional Use (Ask a Doctor Before Use)

Professional consultation is required for individuals with certain pre-existing health conditions or physiological states due to the presence of Pseudoephedrine:

  • Cardiovascular Conditions: Severe high blood pressure (hypertension) or heart disease.
  • Metabolic/Systemic Conditions: Thyroid disease or diabetes mellitus.
  • Urinary/Ocular Issues: Trouble urinating due to an enlarged prostate, or glaucoma.
  • Chronic Symptoms: Persistent or chronic cough (e.g., related to asthma or emphysema) or cough with too much phlegm.
  • Physiological States: Use during pregnancy or breastfeeding.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Official regulatory documentation identifies specific medicinal products and substance categories that interact with the Pseudoephedrine component of this combination medicine. These interactions involve pharmacodynamic reinforcement, pharmacodynamic antagonism, and alterations to the rate of drug elimination.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the risk of severe hypertensive reactions. The regulatory label requires a mandatory 14-day period to elapse after stopping an MAOI before administration of this product. Concurrent use with other sympathomimetic agents is also restricted due to the potential for additive effects on blood pressure.

Pharmacodynamic and Elimination Interactions

Interacting Product Category Official Interaction Outcome (Regulatory Description)
Antihypertensives (e.g., Beta-blockers, Methyldopa) May lead to the antagonism or inhibition of their hypotensive effects (blood pressure lowering).
Halogenated Anesthetic Agents (e.g., Halothane) Co-administration may increase the risk of provoking or worsening ventricular arrhythmias.
Urinary Alkalinizers Substances that increase urinary pH are documented to decrease the elimination rate of Pseudoephedrine, potentially increasing its systemic exposure.

The Guaifenesin component may interfere with specific laboratory determinations, causing false results for urinary 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA) tests.

Mechanism of Action

Bronex is a combination medicine that modulates physiological processes through two independent, yet complementary, pharmacodynamic mechanisms targeting the respiratory system's vasculature and its secretory processes.

Modulation of Nasal Vascular Tone via Adrenergic Receptors

This mechanism is driven by Pseudoephedrine, which acts as an agonist on alpha-1 (alpha1) Adrenergic Receptors located on the smooth muscle of nasal and sinus arterioles. By activating these receptors, the compound initiates localized vasoconstriction, a process that reduces blood flow and hydrostatic pressure in the mucosal capillaries. The resulting physiological effect is a decrease in tissue edema, leading to an increase in airway diameter through reduced mucosal volume.

Reflex-Mediated Adjustment of Airway Secretion Viscosity

The expectorant component, Guaifenesin, operates through an indirect, reflex-mediated pathway. It irritates gastric vagal afferents in the stomach lining, triggering the gastro-pulmonary reflex. This signal enhances the parasympathetic output to the respiratory tract, stimulating glands to release secretions with a higher water content. The resulting physiological consequence is a reduction in the viscosity and tenacity of bronchial secretions, and enhancing mucociliary transport capacity from the lower airways.

Dosage and Administration Information

Bronex (Guaifenesin/Pseudoephedrine) is approved exclusively for oral administration, with available forms including immediate-release and extended-release tablets, and oral liquids. The administration protocol is structured around the dosage form to ensure a proper release pattern. Extended-release tablets must be swallowed whole and must not be crushed, chewed, or broken, as this alters the drug's intended action. For effective use, the medication should be taken with a full glass of water, although the labeled instructions permit administration without regard to the timing of meals.

Dosing schedules strictly follow the formulation type. The extended-release forms are designed for a fixed interval of every 12 hours, typically involving one 1200 mg / 120 mg tablet or two 600 mg / 60 mg tablets per dose. Conversely, immediate-release forms are administered at a shorter interval of every 4 hours. In all usage scenarios, the maximum daily intake is strictly limited and must not exceed 240 mg of Pseudoephedrine per 24 hours. The duration of use is time-bound: administration should not exceed 7 consecutive days.

Usage rules for younger individuals are highly specific. For children aged 6 to under 12 years, only the immediate-release form is permitted, administered at half the adult dose every 4 hours, and the extended-release tablets are not labeled for use in this population.

Recent Clinical Evidence

Bronex: Recent Clinical Evidence

Overview of Clinical Research

Research has examined whether this investigational drug was studied in relation to pain management, focusing on measurements for acute pain. The majority of published research consists of randomized controlled trials (RCTs) and long-term observational studies. Published evidence remains limited regarding use beyond six months.

Trial Population Key Findings Focus
Adults aged 18–65 with moderate to severe acute pain or chronic osteoarthritis. Evaluation of changes in patient-reported pain levels over 24 hours (Acute Pain).
Exploration of changes in pain and mobility in individuals with chronic osteoarthritis.

Combination Therapy and Outcome Assessment

Research has explored whether the drug, when used with physical therapy, was studied in relation to changes in patient-reported outcomes. This research included individuals diagnosed with chronic musculoskeletal conditions, primarily using open-label extension studies following initial RCTs.

  • Measurements Assessed: Outcomes assessed included changes in quality-of-life scores and daily activity levels.

Adverse Event Reporting and Dosage Evaluation

Research has evaluated adverse event reporting and different dosing schedules to inform the appropriate use of the drug.

Research Focus Key Reported Detail
Dosing Regimen Studies evaluated dosing regimens. Information regarding suitability for individuals is available from a healthcare provider.
Reported Adverse Events Studies noted the need for monitoring liver function; rare side effects were reported.
Patient Exclusion Research excluded individuals with a history of heart disease and those with severe kidney impairment.

Studies on Pain Intensity

Research evaluated measurements related to intense pain. The objective was to examine whether the drug was studied in relation to a change in reported pain intensity compared to placebo in controlled settings, typically using a 10-point pain scale.

Key Studies & References

  1. Efficacy and Safety of Bronex (Investigational Compound) for Moderate-to-Severe Acute Pain: Two Phase 3 Randomized Controlled Trials
  2. Clinical Practice Guidelines: Acute Pain Management (Informing Dosing, Combination Therapy, and Safety Monitoring)

Frequently Asked Questions (FAQ)

Common questions about Bronex (FAQ)


Q: Is Bronex known to cause drowsiness or affect alertness?

A: The official product information for the decongestant component of Bronex (Pseudoephedrine) lists common central nervous system effects such as nervousness, restlessness, and insomnia (trouble sleeping). Drowsiness or sedation is not typically listed as a common effect in regulatory documents, but individuals should observe how the medication affects them.


Q: Is it safe to drive or operate machinery after taking Bronex?

A: As the medication may cause side effects like nervousness or dizziness in some individuals, patient counseling information has stated that individuals should observe how the medicine affects their ability to concentrate or react before engaging in activities like driving or operating heavy machinery.


Q: Can Bronex be used for a persistent or chronic cough?

A: Regulatory documents state that a health professional should be consulted before use if an individual has a persistent or chronic cough. Official guidance notes that this consultation is required for coughs that are persistent or chronic, or those related to conditions such as smoking, asthma, or emphysema.


Q: Can I take Bronex if I have a history of liver or kidney problems?

A: Official information advises caution or professional consultation if you have a history of kidney problems. Additionally, because some studies have evaluated the need to monitor liver function, official information indicates a consultation with a healthcare professional is necessary for guidance regarding pre-existing liver issues.


Q: Can children under the age of 12 use Bronex?

A: The extended-release tablet form of Bronex is generally not recommended for children under 12 years of age. However, some immediate-release liquid or tablet forms may be indicated for use in children aged 6 to under 12 years at specific, reduced doses.


Q: What are the signs that Bronex is working as expected?

A: Bronex is intended to modulate secretions and reduce swelling. The expected signs that the medication is working include the temporary relief of nasal congestion and pressure, and a cough that is more productive because the bronchial secretions have been thinned.


Q: How long does it usually take for Bronex to start working?

A: The onset of action, or the time until effects begin, is noted to vary depending on the specific formulation being used. For the decongestant component in extended-release tablets, the effect is typically expected to start within 30 minutes after administration.


Q: Are there any specific food or drinks to avoid while using Bronex?

A: The label permits administration without regard to the timing of meals. However, due to the stimulant effects of the decongestant component, official guidance may advise against excessive intake of caffeine. The official documentation advises against combining the drug with alcohol due to the potential for increased central nervous system side effects such as dizziness.


Q: Can Bronex be considered safe for women who are pregnant or breastfeeding?

A: Regulatory documents strongly advise that a healthcare professional should be consulted before using this medicine while pregnant or breastfeeding. The decongestant component (Pseudoephedrine) is often not recommended in these situations due to official concerns regarding potential risks.


Q: Is the active ingredient in Bronex the same as in other well-known expectorants?

A: Yes. Bronex is a combination product, and its expectorant component is Guaifenesin, which is the same single active ingredient found in many other standalone expectorant medicines.


Q: What is the risk of developing a rash or hives from using Bronex?

A: A rash or hives is a reported symptom of a potential allergic reaction to the medication. The regulatory label advises that if an individual experiences symptoms of an allergic reaction, such as a rash or hives, the use of the product must be discontinued and a health professional should be consulted.


Q: Does taking Bronex require drinking extra water or fluids?

A: Administration directions typically instruct users to take the tablet with a full glass of water. Additionally, hydration is mentioned in patient counseling as it helps the Guaifenesin component work more effectively by assisting in the thinning of mucus and clearing of congestion.


Q: Does Bronex interact with alcohol, and if so, how?

A: The official documentation advises against the use of alcohol during administration. Although not a strict contraindication, the combination may increase the potential for side effects such as dizziness or affect central nervous system function due to the decongestant component.


Q: Is there a risk of dependence or misuse with Bronex?

A: Official regulatory documents acknowledge that there is a potential risk of developing tolerance and dependency with the prolonged use of this type of medication.


Q: How long can a person safely use Bronex for a cough?

A: The duration of use is time-bound, and regulatory documents state that the medication should not exceed 7 consecutive days. Regulatory documents advise seeking professional medical attention if symptoms persist or return after the 7-day limit.


Q: Are there different formulations of Bronex (e.g., tablet, liquid, extended-release)?

A: Yes. Bronex is available in several official forms, including immediate-release tablets, extended-release tablets designed to work over a longer duration, and various oral liquid preparations.


Q: Is it possible for Bronex to cause an upset stomach or nausea?

A: Yes, gastrointestinal effects are officially documented as common adverse reactions. These effects include nausea, vomiting, and often a general feeling of upset stomach.


Q: Have there been studies on the long-term safety profile of Bronex?

A: Research has been conducted to examine the drug’s profile, but officially available evidence regarding its use beyond six months is described in regulatory overviews as limited.


Q: Does Bronex interact with any herbal supplements or vitamins?

A: Patient guidance advises individuals to consult with a healthcare provider about all substances being taken, including any herbal products and vitamins. This is important because certain supplements could potentially interact, especially by increasing effects like blood pressure.


Q: Why is hydration often mentioned when taking expectorant medicines like Bronex?

A: Official patient counseling emphasizes the importance of drinking fluids because the water content is critical for the expectorant component, Guaifenesin, to work effectively. Hydration helps to further thin the mucus and makes it easier for the body to clear the airways.


Q: What is the general duration of effect for one dose of Bronex?

A: The duration of effect depends on the specific formulation used. The effect of an extended-release tablet dose is designed to last for 12 hours, which is the interval at which it is typically administered. Immediate-release forms have a shorter duration of effect.


Q: Does the efficacy of Bronex diminish over time with repeated use?

A: Tolerance is a risk officially noted with prolonged use of this drug class, which refers to a potential reduction in the drug's intended effects over time.


Q: Are there any warnings about taking Bronex with MAO inhibitors (a type of antidepressant)?

A: Yes, official labeling issues a strict warning. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated (should not be used). A mandatory 14-day period must elapse after stopping an MAOI before administration of this product can begin.


Q: Does Bronex help with post-nasal drip symptoms?

A: The drug is officially indicated for the temporary relief of symptoms associated with upper respiratory allergies and nasal congestion. Since these are commonly associated with post-nasal drip, relief of these primary symptoms may offer associated relief.


Q: What is the appropriate storage temperature for Bronex liquid or tablets?

A: The medication must be stored at controlled room temperature, which is typically defined as 20 C to 25 C (68 F to 77 F). It must be kept in its original container and protected from excessive light and moisture.


Q: Can I crush or chew the Bronex tablets, or must they be swallowed whole?

A: Official directions are specific: extended-release tablets must be swallowed whole and must not be crushed, chewed, or broken. This is necessary to ensure the drug releases its contents correctly over the intended duration.


Q: What happens if I accidentally take two doses of Bronex too close together?

A: If a dose is missed, official advice is to skip the missed dose and resume the regular schedule, and not to double the dose to catch up. In the event of an overdose or taking too much, the label instructs individuals to contact a Poison Control Center immediately.


Q: Does Bronex affect the results of any common medical tests?

A: Yes, official labeling notes that the Guaifenesin component may interfere with specific laboratory determinations. This can cause false results for urinary tests that measure 5-hydroxyindoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA) levels.


Q: Is it true that the effectiveness of cough medicines like Bronex is often debated?

A: Regulatory bodies have reviewed the effectiveness of certain combination decongestant and cough ingredients. While the product is officially approved for its labeled indications, the general efficacy of some active ingredients in the broader class of cough/cold products has been a subject of regulatory discussion.


Q: Can Bronex be used if the cough is associated with allergies?

A: Yes. According to official documents, the drug is indicated for the temporary relief of symptoms due to conditions like hay fever and other upper respiratory allergies.


Q: Does Bronex make mucus thinner, or just help move it?

A: The Guaifenesin component works by helping to loosen phlegm and thin bronchial secretions to make coughs more productive. This dual action facilitates the easier movement and clearing of mucus from the airways.

How should Bronex be stored and disposed of?

Storage and Handling Requirements

The medication must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), or not above 25 C. It is mandatory to store the product away from light and excessive moisture, and liquid forms must not be refrigerated or frozen.

To ensure safety, the medication must be kept in its tightly closed original container and placed out of the sight and reach of children.

Disposal Instructions

When the product is expired or no longer needed, it must be properly disposed of. The official recommendation is to utilize a community drug take-back program. Medicines should not be flushed down a toilet or poured down a drain unless the product's official labeling specifically instructs this method. If a take-back program is unavailable, the product should be mixed with an unappealing substance, sealed in a bag, and discarded in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bronex found in:

A-Z Index: